A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）

NCT04659785 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer Extensive Stage

Interventions

DRUG: Fluzoparib
DRUG: Apatinib

Sponsor

Tianjin Medical University Second Hospital